{
    "name": "teduglutide",
    "comment": "Rx",
    "other_names": [
        "Gattex"
    ],
    "classes": [
        "GLP-2 Analogs"
    ],
    "source": "https://reference.medscape.com/drug/gattex-teduglutide-999798",
    "pregnancy": {
        "common": [
            "Available data from case reports in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; pregnant women with short bowel syndrome are at risk for malnutrition, which is associated with adverse maternal and fetal outcomes; severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, no effects on embryo-fetal development were observed with subcutaneous administration to pregnant rats and rabbits during organogenesis at exposures up to 686 times the clinical exposure at recommended human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information regarding presence in human milk, effects on the breastfed infant, or on milk production; drug is present in milk of lactating rats; systemic exposure to a breastfed infant is expected to be low; however, because of the potential for serious adverse reactions in a breastfed infant, including tumorigenicity, advise patients that breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Intestinal obstruction reported; discontinue temporarily and restart when obstruction resolves",
                "Discontinuation of treatment may also result in fluid and electrolyte imbalance; monitor fluid and electrolyte status in patients who discontinue treatment",
                "Fluid overload and congestive heart failure observed in clinical trials"
            ],
            "specific": [
                {
                    "type": "Gallbladder and biliary tract disease",
                    "description": [
                        "Cholecystitis, cholangitis, cholelithiasis, and pancreatitis reported; assess bilirubin, alkaline phosphatase, lipase, and amylase within 6 months prior to starting treatment, and then every 6 months",
                        "If clinically meaningful changes seen, further evaluation including imaging of gallbladder and/or biliary tract recommended; reassess need for continued treatment"
                    ]
                },
                {
                    "type": "Fluid overload and electrolyte imbalance",
                    "description": [
                        "Fluid overload and congestive heart failure observed in clinical studies, deemed to be related to enhanced fluid absorption associated with therapy",
                        "If fluid overload occurs, adjust parenteral support and reassess treatment, especially in patients with underlying cardiovascular disease; if significant cardiac deterioration develops while on therapy, reassess need for continued treatment",
                        "Discontinuation of treatment may also result in fluid and electrolyte imbalance; monitor fluid and electrolyte status in patients who discontinue treatment"
                    ]
                },
                {
                    "type": "Neoplastic growth",
                    "description": [
                        "Based on pharmacologic activity and animal findings, has potential to cause hyperplastic changes, including neoplasia",
                        "In patients at increased risk for malignancy, clinical decision to administer therapy should be considered only if benefits outweigh risks",
                        "Discontinue with active GI malignancy",
                        "In patients who develop active non-gastrointestinal malignancy while receiving therapy, clinical decision to continue should be made based on benefit-risk considerations",
                        "Small bowel neoplasia observed in rats; monitor patients clinically for small bowel neoplasia; if a benign neoplasm found, it should be removed; in case of small bowel cancer, discontinue therapy",
                        "Colorectal polyps",
                        "Colorectal polyps identified during clinical trials",
                        "For adults, perform colonoscopy within 6 months before initiating treatment and after 1 year of treatment",
                        "Colonoscopy/sigmoidoscopy is recommended for all children and adolescents after 1 year of treatment, every 5 years thereafter while on continuous treatment, and if they have new or unexplained gastrointestinal bleeding",
                        "For children and adolescents, perform fecal occult blood testing before initiating treatment and after 1 year of treatment; colonoscopy/sigmoidoscopy required if there is unexplained blood in the stool",
                        "If colorectal cancer diagnosed, discontinue therapy",
                        "See Dosing Considerations for recommendations"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Based on the pharmacodynamic effect of teduglutide, absorption of concomitantly administered oral medications may be increased",
                        "Monitor patients receiving concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions due to potential increased absorption of concomitant drug",
                        "Concomitant drug may require dosage reduction"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "teduglutide increases levels of alprazolam by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "teduglutide increases levels of carbamazepine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "teduglutide increases levels of chlordiazepoxide by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "teduglutide increases levels of chlorpromazine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "teduglutide increases levels of clonazepam by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "teduglutide increases levels of clonidine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "teduglutide increases levels of clorazepate by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colchicine",
            "description": {
                "common": "teduglutide increases levels of colchicine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "teduglutide increases levels of cyclosporine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "teduglutide increases levels of diazepam by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "teduglutide increases levels of digoxin by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "teduglutide increases levels of disopyramide by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "teduglutide increases levels of ethosuximide by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "teduglutide increases levels of flecainide by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "teduglutide increases levels of fluphenazine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "teduglutide increases levels of haloperidol by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "teduglutide increases levels of levothyroxine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "teduglutide increases levels of lithium by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "teduglutide increases levels of lorazepam by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "teduglutide increases levels of loxapine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "teduglutide increases levels of midazolam by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minoxidil",
            "description": {
                "common": "teduglutide increases levels of minoxidil by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxazepam",
            "description": {
                "common": "teduglutide increases levels of oxazepam by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "teduglutide increases levels of phenytoin by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "teduglutide increases levels of pimozide by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "teduglutide increases levels of prazosin by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "teduglutide increases levels of primidone by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procainamide",
            "description": {
                "common": "teduglutide increases levels of procainamide by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "teduglutide increases levels of prochlorperazine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "teduglutide increases levels of quinidine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "teduglutide increases levels of sirolimus by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "teduglutide increases levels of tacrolimus by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "teduglutide increases levels of theophylline by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "teduglutide increases levels of thioridazine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "teduglutide increases levels of thiothixene by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "teduglutide increases levels of trifluoperazine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "teduglutide increases levels of valproic acid by sedation. Use Caution/Monitor. Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "GI stoma complication",
            "percent": "41.9"
        },
        {
            "name": "Abdominal pain",
            "percent": "30"
        },
        {
            "name": "Injection site reactions",
            "percent": "22.4"
        },
        {
            "name": "Abdominal distension",
            "percent": "19.5"
        },
        {
            "name": "Nausea",
            "percent": "18.2"
        },
        {
            "name": "Headaches",
            "percent": "15.9"
        },
        {
            "name": "Abdominal distension",
            "percent": "13.8"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "11.8"
        },
        {
            "name": "Fluid overload",
            "percent": "11.7"
        },
        {
            "name": "Vomiting",
            "percent": "11.7"
        },
        {
            "name": "Flatulence",
            "percent": "9.1"
        },
        {
            "name": "Hypersensitivity",
            "percent": "7.8"
        },
        {
            "name": "Appetite disorders",
            "percent": "6.5"
        },
        {
            "name": "Sleep disturbances",
            "percent": "5.2"
        },
        {
            "name": "Cough",
            "percent": "5.2"
        },
        {
            "name": "Skin hemorrhage",
            "percent": "5.2"
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Cardiac arrest",
            "percent": null
        },
        {
            "name": "cardiac failure",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Cerebral hemorrhage",
            "percent": null
        },
        {
            "name": "Acceleration of neoplastic growth",
            "percent": null
        },
        {
            "name": "Biliary and pancreatic disease",
            "percent": null
        },
        {
            "name": "Intestinal obstruction",
            "percent": null
        },
        {
            "name": "Fluid imbalance and overload",
            "percent": null
        }
    ]
}